Clinical importance of laboratory biomarkers in liver fibrosis
Biochemia medica · 15.10.2022 · 32 (3) · 346-356
DOI: 10.11613/bm.2022.030501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemia medica, online erschienen am 29.09.2022. Verfasst von Goda Aleknavičiūtė-Valienė und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center of Laboratory Medicine,Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Collagen Type IV, Laminin. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatic cirrhosis is a major health problem across the world, causing high morbidity and mortality. This disease has many etiologies, yet the result of chronic hepatic injury is hepatic fibrosis causing cirrhosis and hepatocellular carcinoma, as the liver’s architecture is progressively destroyed. While liver biopsy is currently the gold standard for fibrosis staging, it has significant disadvantages, leading to a growing interest in non-invasive markers. Direct biomarkers – hyaluronic acid, laminin, collagen type III N-peptide, type IV collagen and cholylglycine – are new and rarely applied in routine clinical practice. This is the case primarily because there is no general consensus regarding the clinical application and effectiveness of the individual biomarkers. The usage of these markers in routine clinical practice could be advantageous for patients with liver fibrosis, requiring a simple blood test instead of a biopsy. The former option would be especially attractive for patients who are contraindicated for the latter. This review summarizes recent findings on direct biomarkers of liver fibrosis and highlights their possible applications and potential benefit for liver fibrosis diagnostics and/or staging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Laboratory Medicine,Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
- Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Zitieren
APA
Aleknavičiūtė-Valienė, G., & Banys, V. (2022). Clinical importance of laboratory biomarkers in liver fibrosis. Biochemia medica, 32(3), 346-356. https://doi.org/10.11613/bm.2022.030501
Vancouver
Aleknavičiūtė-Valienė G, Banys V. Clinical importance of laboratory biomarkers in liver fibrosis. Biochemia medica. 2022;32(3):346-356. doi:10.11613/bm.2022.030501
BibTeX
@article{AleknaviitValien2022,
author = {Aleknavičiūtė-Valienė, Goda and Banys, Valdas},
title = {Clinical importance of laboratory biomarkers in liver fibrosis},
journal = {Biochemia medica},
year = {2022},
volume = {32},
number = {3},
pages = {346--356},
doi = {10.11613/bm.2022.030501}
}
EUVIMED